Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Avastin
Pharma
Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study
Ivonescimab showed a 49% PFS benefit against Keytruda in first-line NSCLC. But more hoops lie ahead before the bispecific drug can become king.
Angus Liu
Sep 8, 2024 11:30am
AZ charts new but uncertain path for Imfinzi in liver cancer
Jan 19, 2024 10:00am
FDA signs off on Takeda's colorectal cancer drug Fruzaqla
Nov 9, 2023 10:54am
Merck's Keytruda mostly won out at ESMO, with one notable miss
Oct 24, 2023 9:05am
Roche blasts 'act of counterfeiting' for cancer drug in Pakistan
Sep 25, 2023 2:27pm
FDA rejects Outlook's Avastin reformulation for eye disease
Aug 30, 2023 11:30am
